Novo Shares Slide as CEO Admits Pipeline Problem — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Novo Nordisk shares slumped as management was grilled by investors on drug pricing and M&A strategy, per Reuters
- Novo Nordisk stock was hit by pipeline concerns, with the CEO acknowledging a main problem with the drug pipeline, per Yahoo Finance
Why it matters: Novo Nordisk's stock slid as investors simultaneously challenged management on pricing, M&A, and pipeline concerns, with the CEO publicly acknowledging a pipeline problem — a rare instance of management itself validating the bear case that drove the selloff.
Ask SkimNews
